Type 1 diabetes represents a major risk for future morbidity among the pediatric population, including macrovascular and microvascular complications. Additionally, strict glycemic control might require intensified insulin therapy, leading to increased risk of hypoglycemia and further weight gain, which adversely increased insulin resistance and subsequent cardiovascular risk. Multiple trials of additional antihyperglycemic agents to insulin have been made, aiming for better glycemic control and reduced the risk of cardiovascular disease. This literature review aims to address the effectiveness and safety of additional GLP-1 to insulin therapy on type 1 diabetes among the pediatric population. The main factors contributing to glycemic control include weight loss, decreased insulin requirement and subsequently decreased risk of hypoglycemia, and reduction of HbA1c. We searched in the PubMed database for relevant articles to the article. We used the following Mesh words: GLP-1 receptor agonist, type 1 diabetes, pediatric, and HbA1c. GLP-1 receptor agonist seems to have promising beneficial effects on type 1 diabetes. The addition of these agents resulted in a significant reduction in body weight and insulin requirement, leading to decreased insulin resistance and subsequent reduction in future cardiovascular risk. Nonetheless, HbA1c reduction remains an area of controversy, and further randomized multi-central clinical trials are warranted to establish the efficacy of GLP-1 receptor agonists on glycemic control (HbA1c reduction).
IJPRAS
